Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam

BMC Infectious Diseases

Volumn 17, Issue 1, 2017, Pages

  Popejoy, Myra W ^a   Long, Jianmin ^a   Huntington, Jennifer A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Ceftolozane tazobactam; Complicated intra abdominal infections; Complicated urinary tract infections; Diabetes mellitus

Indexed keywords

CEFTOLOZANE PLUS TAZOBACTAM; LEVOFLOXACIN; MEROPENEM; METRONIDAZOLE; PLACEBO; ANTIINFECTIVE AGENT; CEFTOLOZANE; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID; TAZOBACTAM;

ABDOMINAL INFECTION; ADULT; AGE DISTRIBUTION; AGED; APACHE; ARTICLE; BODY WEIGHT; CLINICAL EFFECTIVENESS; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG SAFETY; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INFECTION RISK; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; POPULATION RESEARCH; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; ANALOGS AND DERIVATIVES; BACTERIAL INFECTIONS; CLINICAL TRIAL; DIABETIC COMPLICATION; INTRAABDOMINAL INFECTIONS; MICROBIOLOGY; MIDDLE AGED; URINARY TRACT INFECTIONS;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CEPHALOSPORINS; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; HUMANS; INTRAABDOMINAL INFECTIONS; LEVOFLOXACIN; MALE; METRONIDAZOLE; MIDDLE AGED; PENICILLANIC ACID; PYELONEPHRITIS; URINARY TRACT INFECTIONS;

EID: 85018758809     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-017-2414-9     Document Type: Article

References (19)

1. Geiss LS, Wang J, Cheng YJ, Thompson TJ, Barker L, Li Y, et al. Prevalence and incidence trends for diagnosed diabetes among adults aged 20 to 79 years, United States, 1980-2012. JAMA. 2014;312:1218-26.
2. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387:1513-30.
3. Benfield T, Jensen JS, Nordestgaard BG. Influence of diabetes and hyperglycaemia on infectious disease hospitalisation and outcome. Diabetologia. 2007;50:549-54.
4. Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care. 2003;26:510-3.
5. Bertoni AG, Saydah S, Brancati FL. Diabetes and the risk of infection-related mortality in the U.S. Diabetes Care. 2001;24:1044-9.
6. Dalrymple LS, Go AS. Epidemiology of acute infections among patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008;3:1487-93.
7. Wang HE, Gamboa C, Warnock DG, Muntner P. Chronic kidney disease and risk of death from infection. Am J Nephrol. 2011;34:330-6.
8. Zhanel GG, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, et al. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs. 2014;74:31-51.
9. Wooley M, Miller B, Krishna G, Hershberger E, Chandorkar G. Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam. Antimicrob Agents Chemother. 2014;58:2249-55.
10. Zerbaxa (ceftolozane and tazobactam) [prescribing information]. Whitehouse Station; Merck Sharpe & Dohme Corp.; 2015.
11. Zerbaxa (ceftolozane and tazobactam) [summary of product characteristics]. Hoddesdon, Hertforshire; Merck Sharpe & Dohme Ltd.; 2016.
12. Solomkin J, Hershberger E, Miller B, Popejoy M, Friedland I, Steenbergen J, et al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis. 2015;60:1462-71.
13. Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet. 2015;385:1949-56.
14. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213-26.
15. Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: a review of pathogenesis. Indian J Endocrinol Metab. 2012;16(suppl 1):S27-36.
16. Grabe M, Bjerklund-Johansen TE, Botto H, Wullt B, Çek M, Naber KG, et al. Guidelines on urological infections. 2012. http://uroweb.org/wp-content/uploads/19-Urological-infections_LR2.pdf. Accessed 1 May 2017.
17. Tsai C-C, Lee J-J, Liu TP, Ko W-C, Wu C-J, Pan C-F, et al. Effects of age and diabetes mellitus on clinical outcomes in patients with peritoneal dialysis-related peritonitis. Surg Infect (Larchmt). 2013;14:540-6.
18. Thomsen RW, Hundborg HH, Lervang H-H, Johnsen SP, Schønheyder HC, Sørensen HT. Diabetes mellitus as a risk and prognostic factor for community-acquired bacteremia due to enterobacteria: a 10-year, population-based study among adults. Clin Infect Dis. 2005;40:628-31.
19. Pertel PE, Haverstock D. Risk factors for a poor outcome after therapy for acute pyelonephritis. BJU Int. 2006;98:141-7.